Tonghua Dongbao Pharmaceutical Management

Management criteria checks 3/4

Tonghua Dongbao Pharmaceutical's CEO is Sheng Leng Chun, appointed in May 2020, has a tenure of 4.5 years. directly owns 0.12% of the company’s shares, worth CN¥19.36M. The average tenure of the management team and the board of directors is 4.5 years and 4.5 years respectively.

Key information

Sheng Leng Chun

Chief executive officer

CN¥3.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	4.5yrs
CEO ownership	0.1%
Management average tenure	4.5yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO

Sheng Leng Chun (50 yo)

4.5yrs

Tenure

CN¥3,728,800

Compensation

Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sheng Leng Chun	GM & Director	4.5yrs	CN¥3.73m	0.12% CN¥ 19.4m
Junyu Chi	Chief Accountant	4.5yrs	CN¥852.40k	no data
Hong Chen	Chief Engineer & Deputy GM	10.7yrs	CN¥527.20k	0.015% CN¥ 2.5m
Guodong Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.014% CN¥ 2.2m
Wenhai Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.031% CN¥ 5.1m
Zhiqiang Du	Deputy General Manager	3yrs	CN¥1.45m	no data
Fan Su	Deputy GM & Board Secretary	4.4yrs	CN¥992.50k	no data

4.5yrs

Average Tenure

50yo

Average Age

Experienced Management: 600867's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sheng Leng Chun	GM & Director	10.7yrs	CN¥3.73m	0.12% CN¥ 19.4m
Guodong Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.014% CN¥ 2.2m
Wenhai Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.031% CN¥ 5.1m
Junye Wang	Chairman of the Supervisory Board	4.2yrs	CN¥1.17m	0.12% CN¥ 19.6m
Fu Bo Cao	Supervisor	4.5yrs	CN¥173.20k	no data
Wei Wang	Director	4.2yrs	no data	no data
Qingxia He	Employee Representative Supervisor	4.5yrs	no data	no data
Jiahong Li	Chairman of the Board	4.5yrs	CN¥173.20k	0.27% CN¥ 44.8m
Yan Bi	Independent Director	9.3yrs	CN¥100.00k	no data
Dai Xu	Independent Director	2.5yrs	CN¥100.00k	no data
Li Xu	Independent Director	2.5yrs	CN¥100.00k	no data
Jianchun Zhen	Director	1.2yrs	no data	no data

4.5yrs

Average Tenure

50yo

Average Age

Experienced Board: 600867's board of directors are considered experienced (4.5 years average tenure).

Tonghua Dongbao Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.059 (vs CN¥0.14 in 3Q 2023)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

Now 21% overvalued

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 2Q 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.64 in FY 2021)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

First quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.64 (vs CN¥0.46 in FY 2020)

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

New 90-day low: CN¥11.82

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥0.46

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age